

Donald R Vandevanter

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5137475/publications.pdf>

Version: 2024-02-01

88
papers

4,329
citations

126907

33
h-index

110387

64
g-index

88
all docs

88
docs citations

88
times ranked

4190
citing authors

#	ARTICLE	IF	CITATIONS
1	A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis. <i>Nature</i> , 2000, 405, 962-966.	27.8	971
2	Decade-long bacterial community dynamics in cystic fibrosis airways. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 5809-5814.	7.1	543
3	CFTR modulator theratyping: Current status, gaps and future directions. <i>Journal of Cystic Fibrosis</i> , 2019, 18, 22-34.	0.7	208
4	Treatment with tobramycin solution for inhalation reduces hospitalizations in young CF subjects with mild lung disease. <i>Pediatric Pulmonology</i> , 2004, 38, 314-320.	2.0	116
5	Cystic fibrosis in young children: A review of disease manifestation, progression, and response to early treatment. <i>Journal of Cystic Fibrosis</i> , 2016, 15, 147-157.	0.7	108
6	Oral, inhaled, and intravenous antibiotic choice for treating pulmonary exacerbations in cystic fibrosis. <i>Pediatric Pulmonology</i> , 2013, 48, 666-673.	2.0	99
7	Risk factors for rate of decline in FEV1 in adults with cystic fibrosis. <i>Journal of Cystic Fibrosis</i> , 2012, 11, 405-411.	0.7	96
8	Anti-PcrV antibody in cystic fibrosis: A novel approach targeting <i>Pseudomonas aeruginosa</i> airway infection. <i>Pediatric Pulmonology</i> , 2014, 49, 650-658.	2.0	90
9	Antimicrobial susceptibility testing (AST) and associated clinical outcomes in individuals with cystic fibrosis: A systematic review. <i>Journal of Cystic Fibrosis</i> , 2019, 18, 236-243.	0.7	84
10	Standardized Treatment of Pulmonary Exacerbations (STOP) study: Physician treatment practices and outcomes for individuals with cystic fibrosis with pulmonary Exacerbations. <i>Journal of Cystic Fibrosis</i> , 2017, 16, 600-606.	0.7	76
11	Fluctuations in airway bacterial communities associated with clinical states and disease stages in cystic fibrosis. <i>PLoS ONE</i> , 2018, 13, e0194060.	2.5	76
12	Standardized Treatment of Pulmonary Exacerbations (STOP) study: Observations at the initiation of intravenous antibiotics for cystic fibrosis pulmonary exacerbations. <i>Journal of Cystic Fibrosis</i> , 2017, 16, 592-599.	0.7	69
13	Defining antimicrobial resistance in cystic fibrosis. <i>Journal of Cystic Fibrosis</i> , 2018, 17, 696-704.	0.7	66
14	A phase 3, open-label, randomized trial to evaluate the safety and efficacy of levofloxacin inhalation solution (APT-1026) versus tobramycin inhalation solution in stable cystic fibrosis patients. <i>Journal of Cystic Fibrosis</i> , 2015, 14, 507-514.	0.7	62
15	Reconciling Antimicrobial Susceptibility Testing and Clinical Response in Antimicrobial Treatment of Chronic Cystic Fibrosis Lung Infections. <i>Clinical Infectious Diseases</i> , 2019, 69, 1812-1816.	5.8	62
16	A phase 3, multi-center, multinational, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of levofloxacin inhalation solution (APT-1026) in stable cystic fibrosis patients. <i>Journal of Cystic Fibrosis</i> , 2016, 15, 495-502.	0.7	59
17	Trends in the use of routine therapies in cystic fibrosis: 1995-2005. <i>Pediatric Pulmonology</i> , 2010, 45, 1167-1172.	2.0	58
18	Assessing time to pulmonary function benefit following antibiotic treatment of acute cystic fibrosis exacerbations. <i>Respiratory Research</i> , 2010, 11, 137.	3.6	53

#	ARTICLE	IF	CITATIONS
19	Characterizing aggressiveness and predicting future progression of CF lung disease. <i>Journal of Cystic Fibrosis</i> , 2009, 8, S15-S19.	0.7	52
20	Association of High-Dose Ibuprofen Use, Lung Function Decline, and Long-Term Survival in Children with Cystic Fibrosis. <i>Annals of the American Thoracic Society</i> , 2018, 15, 485-493.	3.2	52
21	Use of ibuprofen to assess inflammatory biomarkers in induced sputum: Implications for clinical trials in cystic fibrosis. <i>Journal of Cystic Fibrosis</i> , 2015, 14, 720-726.	0.7	51
22	How much do Pseudomonas biofilms contribute to symptoms of pulmonary exacerbation in cystic fibrosis?. <i>Pediatric Pulmonology</i> , 2005, 39, 504-506.	2.0	50
23	Tobramycin administered by the TOBI [®] Podhaler [®] for persons with cystic fibrosis: a review. <i>Medical Devices: Evidence and Research</i> , 2011, 4, 179.	0.8	50
24	Efficacy and safety of ataluren in patients with nonsense-mutation cystic fibrosis not receiving chronic inhaled aminoglycosides: The international, randomized, double-blind, placebo-controlled Ataluren Confirmatory Trial in Cystic Fibrosis (ACT CF). <i>Journal of Cystic Fibrosis</i> , 2020, 19, 595-601.	0.7	49
25	Culture-Based and Culture-Independent Bacteriologic Analysis of Cystic Fibrosis Respiratory Specimens. <i>Journal of Clinical Microbiology</i> , 2016, 54, 613-619.	3.9	48
26	Clinical applications of pulmonary delivery of antibiotics. <i>Advanced Drug Delivery Reviews</i> , 2015, 85, 1-6.	13.7	46
27	A Randomized Clinical Trial of Antimicrobial Duration for Cystic Fibrosis Pulmonary Exacerbation Treatment. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021, 204, 1295-1305.	5.6	45
28	Forced Expiratory Volume in 1 Second Variability Helps Identify Patients with Cystic Fibrosis at Risk of Greater Loss of Lung Function. <i>Journal of Pediatrics</i> , 2016, 169, 116-121.e2.	1.8	44
29	Antibiotic treatment of signs and symptoms of pulmonary exacerbations: A comparison by care site. <i>Pediatric Pulmonology</i> , 2015, 50, 431-440.	2.0	43
30	Study design considerations for the Standardized Treatment of Pulmonary Exacerbations 2 (STOP2): A trial to compare intravenous antibiotic treatment durations in CF. <i>Contemporary Clinical Trials</i> , 2018, 64, 35-40.	1.8	42
31	Safety and efficacy of prolonged levofloxacin inhalation solution (APT-1026) treatment for cystic fibrosis and chronic Pseudomonas aeruginosa airway infection. <i>Journal of Cystic Fibrosis</i> , 2016, 15, 634-640.	0.7	40
32	Pulmonary outcome prediction (POP) tools for cystic fibrosis patients. <i>Pediatric Pulmonology</i> , 2010, 45, 1156-1166.	2.0	39
33	Treatment and demographic factors affecting time to next pulmonary exacerbation in cystic fibrosis. <i>Journal of Cystic Fibrosis</i> , 2015, 14, 763-769.	0.7	38
34	IV-treated pulmonary exacerbations in the prior year: An important independent risk factor for future pulmonary exacerbation in cystic fibrosis. <i>Journal of Cystic Fibrosis</i> , 2016, 15, 372-379.	0.7	35
35	Relationship of Antibiotic Treatment to Recovery after Acute FEV ₁ Decline in Children with Cystic Fibrosis. <i>Annals of the American Thoracic Society</i> , 2017, 14, 937-942.	3.2	35
36	Probability of IV antibiotic retreatment within thirty days is associated with duration and location of IV antibiotic treatment for pulmonary exacerbation in cystic fibrosis. <i>Journal of Cystic Fibrosis</i> , 2016, 15, 783-790.	0.7	34

#	ARTICLE	IF	CITATIONS
37	Developing Inhaled Antibiotics in Cystic Fibrosis: Current Challenges and Opportunities. <i>Annals of the American Thoracic Society</i> , 2019, 16, 534-539.	3.2	33
38	Treatment Setting and Outcomes of Cystic Fibrosis Pulmonary Exacerbations. <i>Annals of the American Thoracic Society</i> , 2018, 15, 225-233.	3.2	32
39	Outcome measures for clinical trials assessing treatment of cystic fibrosis lung disease. <i>Clinical Investigation</i> , 2012, 2, 163-175.	0.0	31
40	Trisomy 8 in primary esthesioneuroblastoma. <i>Cancer Genetics and Cytogenetics</i> , 1991, 57, 133-136.	1.0	30
41	Measures of Cystic Fibrosis Airway Microbiota during Periods of Clinical Stability. <i>Annals of the American Thoracic Society</i> , 2019, 16, 1534-1542.	3.2	26
42	Improvements in Lung Function and Height among Cohorts of 6-Year-Olds with Cystic Fibrosis from 1994 to 2012. <i>Journal of Pediatrics</i> , 2014, 165, 1091-1097.e2.	1.8	24
43	Association between the introduction of a new cystic fibrosis inhaled antibiotic class and change in prevalence of patients receiving multiple inhaled antibiotic classes. <i>Journal of Cystic Fibrosis</i> , 2015, 14, 370-375.	0.7	24
44	Antimicrobial resistance in cystic fibrosis: A Delphi approach to defining best practices. <i>Journal of Cystic Fibrosis</i> , 2020, 19, 370-375.	0.7	24
45	Building global development strategies for cf therapeutics during a transitional cfr modulator era. <i>Journal of Cystic Fibrosis</i> , 2020, 19, 677-687.	0.7	24
46	Y chromosome loss in chronic myeloid leukemia detected in both normal and malignant cells by interphase fluorescence in situ hybridization. <i>Genes Chromosomes and Cancer</i> , 1994, 11, 141-145.	2.8	22
47	Trends in the clinical characteristics of the U.S. cystic fibrosis patient population from 1995 to 2005. <i>Pediatric Pulmonology</i> , 2008, 43, 739-744.	2.0	21
48	Aerosolized antibiotic therapy for chronic cystic fibrosis airway infections: continuous or intermittent?. <i>Respiratory Medicine</i> , 2011, 105, S9-S17.	2.9	21
49	Lung function changes before and after pulmonary exacerbation antimicrobial treatment in cystic fibrosis. <i>Pediatric Pulmonology</i> , 2020, 55, 828-834.	2.0	21
50	Determination of polymyxin E1 in rat plasma by high-performance liquid chromatography. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2003, 789, 365-372.	2.3	20
51	BMI fails to identify poor nutritional status in stunted children with CF. <i>Journal of Cystic Fibrosis</i> , 2017, 16, 158-160.	0.7	20
52	Decline in lung function does not predict future decline in lung function in cystic fibrosis patients. <i>Pediatric Pulmonology</i> , 2015, 50, 856-862.	2.0	19
53	Microbial diversity in the cystic fibrosis airways: where is thy sting?. <i>Future Microbiology</i> , 2012, 7, 801-803.	2.0	18
54	Changing thresholds and incidence of antibiotic treatment of cystic fibrosis pulmonary exacerbations, 1995-2005. <i>Journal of Cystic Fibrosis</i> , 2013, 12, 332-337.	0.7	18

#	ARTICLE	IF	CITATIONS
55	Finding the relevance of antimicrobial stewardship for cystic fibrosis. <i>Journal of Cystic Fibrosis</i> , 2020, 19, 511-520.	0.7	18
56	CFTR modulators and pregnancy: Our work has only just begun. <i>Journal of Cystic Fibrosis</i> , 2016, 15, 6-7.	0.7	15
57	Feasibility of placebo-controlled trial designs for new CFTR modulator evaluation. <i>Journal of Cystic Fibrosis</i> , 2017, 16, 496-498.	0.7	15
58	Applying clinical outcome variables to appropriate aerosolized antibiotics for the treatment of patients with cystic fibrosis. <i>Respiratory Medicine</i> , 2011, 105, S18-S23.	2.9	14
59	Antimicrobial resistance: Concerns of healthcare providers and people with CF. <i>Journal of Cystic Fibrosis</i> , 2021, 20, 407-412.	0.7	13
60	The use of antimicrobial susceptibility testing in pediatric cystic fibrosis pulmonary exacerbations. <i>Journal of Cystic Fibrosis</i> , 2019, 18, 851-856.	0.7	12
61	Epidemiologic Study of Cystic Fibrosis: 25 years of observational research. <i>Pediatric Pulmonology</i> , 2021, 56, 823-836.	2.0	11
62	Measuring the impact of CFTR modulation on sweat chloride in cystic fibrosis: Rationale and design of the CHEC-SC study. <i>Journal of Cystic Fibrosis</i> , 2021, 20, 965-971.	0.7	11
63	Evaluating assumptions of definition-based pulmonary exacerbation endpoints in cystic fibrosis clinical trials. <i>Journal of Cystic Fibrosis</i> , 2021, 20, 39-45.	0.7	9
64	Evidence of diminished FEV1 and FVC in 6-year-olds followed in the European cystic fibrosis patient registry, 2007-2009. <i>Journal of Cystic Fibrosis</i> , 2013, 12, 786-789.	0.7	8
65	Innovating cystic fibrosis clinical trial designs in an era of successful standard of care therapies. <i>Current Opinion in Pulmonary Medicine</i> , 2017, 23, 530-535.	2.6	8
66	Association of Inhaled Antibiotics in Addition to Standard Intravenous Therapy and Outcomes of Pediatric Inpatient Pulmonary Exacerbations. <i>Annals of the American Thoracic Society</i> , 2020, 17, 1590-1598.	3.2	8
67	Resolution of DNA fragments from 23 kilobases to 6 megabases by biphasic linear pulse ramping. <i>Nucleic Acids Research</i> , 1992, 20, 1148-1148.	14.5	7
68	<i>Pseudomonas aeruginosa</i> antimicrobial susceptibility test (AST) results and pulmonary exacerbation treatment responses in cystic fibrosis. <i>Journal of Cystic Fibrosis</i> , 2021, 20, 257-263.	0.7	7
69	Changes in symptom scores as a potential clinical endpoint for studies of cystic fibrosis pulmonary exacerbation treatment. <i>Journal of Cystic Fibrosis</i> , 2021, 20, 36-38.	0.7	7
70	Management of chronic <i>Pseudomonas aeruginosa</i> infection with inhaled levofloxacin in people with cystic fibrosis. <i>Future Microbiology</i> , 2021, 16, 1087-1104.	2.0	7
71	In Vitro Antibiotic Susceptibility of Initial <i>Pseudomonas aeruginosa</i> Isolates From United States Cystic Fibrosis Patients. <i>Journal of the Pediatric Infectious Diseases Society</i> , 2015, 4, 151-154.	1.3	6
72	Comparison of FEV1 reference equations for evaluating a cystic fibrosis therapeutic intervention. <i>Pediatric Pulmonology</i> , 2017, 52, 1013-1019.	2.0	6

#	ARTICLE	IF	CITATIONS
73	Cystic fibrosis clinical characteristics associated with dornase alfa treatment regimen change. <i>Pediatric Pulmonology</i> , 2018, 53, 43-49.	2.0	6
74	Changes in airway bacterial communities occur soon after initiation of antibiotic treatment of pulmonary exacerbations in cystic fibrosis. <i>Journal of Cystic Fibrosis</i> , 2022, , .	0.7	6
75	Antipseudomonal treatment decisions during CF exacerbation management. <i>Journal of Cystic Fibrosis</i> , 2022, 21, 753-758.	0.7	4
76	Retracing changes in cystic fibrosis understanding and management over the past twenty years. <i>Journal of Cystic Fibrosis</i> , 2022, 21, 3-9.	0.7	3
77	Potential for Therapeutic Benefit among Cystic Fibrosis Populations Excluded from Clinical Trials or Labeling of Marketed Therapies. <i>Annals of the American Thoracic Society</i> , 2016, 13, 1890-1893.	3.2	2
78	Health care costs in a randomized trial of antimicrobial duration among cystic fibrosis patients with pulmonary exacerbations. <i>Journal of Cystic Fibrosis</i> , 2022, , .	0.7	2
79	Electrophoretic isolation of extrachromosomal DNA from tumor cells. <i>Genes Chromosomes and Cancer</i> , 1995, 12, 262-271.	2.8	1
80	The challenge of improving outcomes for patients with CF sinonasal disease. <i>Journal of Cystic Fibrosis</i> , 2014, 13, 361-362.	0.7	1
81	Efficacy measures for clinical trials: A review series. <i>Journal of Cystic Fibrosis</i> , 2016, 15, 415.	0.7	1
82	The challenges of maintaining momentum in CF drug development and approval - Commentary. <i>Journal of Cystic Fibrosis</i> , 2017, 16, 170-171.	0.7	1
83	The Pitfalls of Polypharmacy and Precision Medicine in Cystic Fibrosis. <i>Annals of the American Thoracic Society</i> , 2019, 16, 819-820.	3.2	1
84	Leveraging early markers of cystic fibrosis structural lung disease to improve outcomes. <i>European Respiratory Journal</i> , 2020, 55, 2000105.	6.7	1
85	The march towards CFTR modulator access for all people with CF: The end of the beginning. <i>Journal of Cystic Fibrosis</i> , 2021, 20, 185-187.	0.7	1
86	First Bacterial Infection as an Alternative Clinical End Point for Regulatory Approval of Agents Targeting the Primary Cystic Fibrosis Defect. <i>Journal of Pediatrics</i> , 2005, 147, 332-334.	1.8	0
87	Anti-Infective Therapies in Cystic Fibrosis. <i>Milestones in Drug Therapy</i> , 2017, , 153-169.	0.1	0
88	Cystic fibrosis: definition, severity and impact of pulmonary exacerbations. , 0, , 25-37.		0